Skip to main content

12.11.2015 | Onkologie | Onlineartikel

Small-cell lung cancer: established and novel approaches

Small-cell lung cancer (SCLC) accounts for 14 % of all lung cancers. It is initially sensitive to chemotherapy and radiation therapy, but resistance tends to develop rapidly, which leads to high recurrence rates. Outcomes with second-line treatments are poor, with 5-year survival rates of only 5 %. Topotecan is the only approved agent in the second-line setting.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten